// App-Quantinova.ai

: Late Breaking Abstract - Two Phase 3 Randomized Clinical Trials of Gefapixant, a P2X3 Receptor Antagonist, in Refractory or Unexplained Chronic Cough (COUGH-1 and COUGH-2

Researchers

Presenter

  • Lorcan McGarvey

Principal Investigators

  • Surinder Birring

  • Alyn Morice

  • Peter Dicpinigaitis

  • Ian Pavord

  • Jonathan Schelfhout

  • Allison Martin Nguyen

  • Qing Li

  • Anjela Tzontcheva

  • Beata Iskold

  • Stuart Green

  • Carmen La Rosa

  • David Muccino

  • Jaclyn Smith

Medical Centers

  • Centre for Experimental Medicine, Queen's University Belfast, Belfast, United Kingdom

  • Centre of Human & Aerospace Physiological Sciences, King’s College London, King's Health Partners, London, United Kingdom

  • The Hull York Medical School, Cottingham, United Kingdom

  • Albert Einstein College of Medicine, Rheumatology, Montefiore Medical Center, New York, United States of America

  • Oxford NIHR Respiratory BRC, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom

  • Merck & Co., Inc., Kenilworth, United States of America

  • University of Manchester and Manchester University NHS Trust, University of MancManchester, United Kingdom

Locations

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • X-Ray Repair Cross Complementing 1

Drug/Treatment

  • Gefapixant

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • III

Study Id's

  • NCT03449134

  • NCT03449147

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved